Summary & Overview
HCPCS J1325: Epoprostenol Injection, 0.5 mg
HCPCS Level II code J1325 designates a 0.5 mg vial of epoprostenol, an intravenous prostacyclin used primarily in the management of pulmonary arterial hypertension. As a high-cost, parenteral specialty drug, accurate use of J1325 affects hospital, infusion center, and clinic billing as well as payer coverage and prior authorization workflows nationwide. The code matters nationally because it ties directly to drug acquisition costs, reimbursement pathway selection, and site-of-care considerations for patients requiring continuous or intermittent infusion therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for epoprostenol administration, typical sites of service where J1325 is billed, common modifiers used with HCPCS Level II drug codes, and guidance on where to find related billing components. The publication summarizes benchmark considerations, payer coverage patterns, and policy developments that influence utilization management and reimbursement for parenteral prostacyclins. Data not available in the input is noted where applicable, and the report focuses on national-level implications rather than state-specific policies.
Billing Code Overview
HCPCS Level II code J1325 represents an injection of epoprostenol, 0.5 mg. This code denotes administration of a prostacyclin analog used for the treatment of pulmonary arterial hypertension and other conditions requiring vasodilatory and antiplatelet effects.
-
Service type: Injectable medication administration (parenteral drug)
-
Typical site of service: Hospital inpatient, hospital outpatient department, infusion center, or ambulatory clinic where parenteral therapies are administered
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J1325 (epoprostenol injection, 0.5 mg) is an adult with advanced pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension requiring parenteral prostacyclin therapy. The patient often presents to a specialized pulmonary hypertension clinic or an infusion center for medication initiation, dose titration, or ongoing maintenance therapy. Initiation commonly occurs after cardiopulmonary evaluation including right heart catheterization, echocardiography, and clinical risk assessment. The clinical workflow includes medication preparation by pharmacy, education on continuous intravenous infusion pump management, vascular access placement or assessment (e.g., tunneled central venous catheter), baseline vitals and laboratory checks, supervised infusion start or adjustment, observation for side effects (hypotension, flushing, jaw pain, headache, infusion-site infection), and documentation of dose administered. Routine encounters include periodic home infusion nursing visits, outpatient infusion center visits for bolus dosing or transitions, and coordination with pulmonology, cardiology, and specialty pharmacy for supplies and billing. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and specialized clinics; initiation may also occur inpatient when close monitoring is needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) |